Q1 2026 · 13F-HR
First Turn Management, LLCholdings as filed
Filed 2026-05-15 · accession 0001993440-26-000002
$895.1M
Reported value
33
Positions
2026-03-31
Period end
The Brief · First Turn Management, LLC · Q1 2026
AI · grounded in 13F
First Turn Management, LLC closed its position in GH for a reduction of $27.7M. The fund established several new positions, including ELVN for $24.5M and CELC for $24.0M. Additionally, the fund accumulated shares of UTHR, increasing its position by 64.7%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $62.1M | 6.94% | 104,726 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $51.9M | 5.80% | 465,869 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $51.7M | 5.77% | 695,718 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $45.8M | 5.11% | 786,844 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $45.5M | 5.09% | 468,376 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $43.2M | 4.83% | 513,770 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $40.6M | 4.54% | 248,475 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $37.9M | 4.24% | 370,344 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $37.0M | 4.13% | 400,464 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $36.5M | 4.07% | 947,339 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $33.0M | 3.68% | 1,190,118 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC. | $31.9M | 3.56% | 188,772 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $29.1M | 3.25% | 873,838 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $25.6M | 2.86% | 2,017,284 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $24.5M | 2.73% | 623,839 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $24.0M | 2.69% | 210,578 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $21.9M | 2.45% | 446,390 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $21.2M | 2.37% | 254,672 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $18.7M | 2.09% | 283,700 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $18.5M | 2.07% | 220,921 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $18.5M | 2.06% | 148,093 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $17.9M | 2.00% | 558,336 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $17.8M | 1.99% | 911,337 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $17.5M | 1.95% | 76,300 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $17.3M | 1.93% | 2,256,109 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $17.2M | 1.92% | 326,694 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $17.0M | 1.90% | 422,023 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $16.2M | 1.81% | 81,077 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $14.0M | 1.57% | 867,639 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $13.7M | 1.53% | 42,441 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $11.5M | 1.28% | 768,662 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $10.1M | 1.12% | 615,489 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $5.9M | 0.66% | 315,563 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.